Clinical Impact of <i>MTAP</i> Rearrangement in Pediatric Acute Lymphoblastic Leukemia: Insights From Whole Transcriptome Analysis
MTAP rearrangement defines a distinct and clinically adverse subset of pediatric ALL characterized by specific fusion architecture and an unfavorable co-mutation pattern. Beyond its diagnostic value, MTAP-r represents a promising biomarker for trial enrollment and future risk-adapted strategies. Confirmation of independent prognostic impact and therapeutic utility will require multivariable analyses and prospective, biomarker-driven studies.
Authors
- Sidong Zhang (ORCID: https://orcid.org/0009-0002-6310-6155)
- Yufeng Liu (ORCID: https://orcid.org/0000-0002-8140-7034)
- Yadong Song (ORCID: https://orcid.org/0000-0002-3067-5039)
- Bai Li (ORCID: https://orcid.org/0000-0002-7033-9750)
- Zhengyu Wu (ORCID: https://orcid.org/0009-0002-7064-7478)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Institute of Hematology & Blood Diseases Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
Publication Details
- Journal
- Pediatric Blood & Cancer
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1002/mpo.70012
- Primary Topic
- Acute Lymphoblastic Leukemia research
- Type
- article
- Field-Weighted Citation Impact
- 0.00